# CD34+ Selected ASCT for Aggressive Lymphomas

> **NCT02646098** · PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 64 (actual)

## Conditions studied

- Malignant Non-Hodgkin Lymphomas

## Interventions

- **PROCEDURE:** CD34+ cell selection

## Key facts

- **NCT ID:** NCT02646098
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-02
- **Primary completion:** 2018-10-11
- **Final completion:** 2023-11-30
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02646098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02646098, "CD34+ Selected ASCT for Aggressive Lymphomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02646098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*